Bogle Investment Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Bogle Investment Management’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-183,440	Closed	-$1.97M	–	356
2016 Q2	$1.97M	Sell	183,440 -85,604	-32%	-$913K	0.14%	176
2016 Q1	$2.97M	Buy	269,044 +257,694	+2,270%	+$2.56M	0.2%	142
2015 Q4	$138K	Sell	11,350 -115,995	-91%	-$1.81M	0.01%	356
2015 Q3	$2.08M	Buy	127,345 +5,720	+5%	+$126K	0.15%	170
2015 Q2	$2.58M	Buy	+121,625	New	+$2.18M	0.19%	151
2014 Q4	–	Sell	-129,736	Closed	-$1.86M	–	357
2014 Q3	$1.86M	Buy	129,736 +16,689	+15%	+$240K	0.12%	186
2014 Q2	$1.7M	Buy	113,047 +41,454	+58%	+$500K	0.11%	201
2014 Q1	$959K	Buy	+71,593	New	+$767K	0.07%	271

Other funds holding AVDL

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Bogle Investment Management's AVDL Position: Q3 2016 in Review

Bogle Investment Management sold out of Avadel Pharmaceuticals (AVDL) in Q3 2016, closing a stake of 183,440 shares — an estimated $1.97M sold.

Bogle Investment Management first reported a position in AVDL in Q1 2014 and held it in 8 quarters. The position peaked at $2.97M in Q1 2016. 87 funds tracked by Wall St. Rank hold AVDL as of Q3 2016.

Bogle Investment Management reported no remaining Avadel Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
Bogle Investment Management sold 183,440 Avadel Pharmaceuticals shares in Q3 2016, an estimated $1.97M.
Bogle Investment Management first reported a position in Avadel Pharmaceuticals in Q1 2014 and held it in 8 quarters.
Bogle Investment Management's Avadel Pharmaceuticals position peaked at $2.97M in Q1 2016.
87 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q3 2016.

Based on Bogle Investment Management's 13F filing for Q3 2016, filed 14 Nov 2016.